Introduction: Chemotherapy (CT) is widely used for neuroendocrine tumors (NET) but there are no validated biomarkers to predict response. The Ki-67 proliferation index has been proposed as a means of selecting patients for CT but robust data are lacking.
Aim(s): We investigated the relationship between response and Ki-67, and sought to define a cut-off for patient stratification.
Materials and methods: We reviewed data from 152 patients treated with 5-fluorouracil, cisplatin and streptozocin (FCiSt). Tumors were graded according to Ki-67 index: low ≤5%, intermediate 5-20% and high >20%. Radiological response was assessed by RECIST and survival calculated from start of chemotherapy to death. To explore the utility of Ki-67 as a marker of response, we calculated the likelihood ratio and performed receiver operating characteristic (ROC) analysis.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Alexa Childs
To read results and conclusion, please login ...
Further abstracts you may be interested in